Hunter Hall Global Value Limited
Monthly Performance Report for July
Says
Australian liver cancer treatment company Sirtex rose 34% over the month after delivering outstanding June quarterly results and 2009 financial year results. Product revenue rose 72% for the year to June 2009, to exceed $65.6m, with European and U.S sales growing 117% and 28% respectively. Operational cash flow rose to $20m, up 426% on the previous corresponding period, while net profit before tax surged 640%. With very pleasing momentum, a strong balance sheet, nil borrowings and rising cash flow, we believe Sirtex has a strong outlook.
http://www.aspectfinancial.com.au/docserver/00977442.pdf?fileid=00977442&datedir=20090814&edt=MjAwOS0wOC0xNCsxMToyNTo1MCsxMjArNjEwMDk1ODErZXRyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBhZ2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYWwvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true
Hunter Hall Global Value LimitedMonthly Performance Report for...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $326.7K | 1.850M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 481601 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2315334 | 24 |
View Market Depth
| Last trade - 15.39pm 07/08/2024 (20 minute delay) ? |
| SRX (ASX) Chart |